Rogin Subedi, MD
Cardiovascular Disease · Ocean Springs, MSNPI 1154797991
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (42.6%), grants and travel and lodging — rather than concentrated in one kind of arrangement. 33 manufacturers reported payments, led by Medtronic at 34.1% of the total. Reporting peaked in 2024 at $7,587 and has fallen 78.2% since, to $1,651 in 2025.
Across 242 payments — averaging $100.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$8K
- Inari Medical, Inc.$5K
- Boston Scientific$4K
- Angiodynamics, Inc.$2K
- Abbott$2K
- Abiomed$484
- plus $3K from 27 others
What the payments were for
- Speaking & faculty fees$3,10013%
- Grants$5,74924%
- Travel & lodging$4,40218%
- Food & beverage$10,34843%
- Education$6973%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 62 | $8,292 |
| Inari Medical, Inc. | 32 | $5,013 |
| Boston Scientific | 13 | $4,146 |
| Angiodynamics, Inc. | 18 | $1,661 |
| Abbott | 26 | $1,580 |
| Abiomed | 10 | $484 |
| Amgen | 7 | $364 |
| Shockwave Medical, Inc | 3 | $359 |
| E.r. Squibb & Sons, L.L.C. | 5 | $242 |
| AstraZeneca | 4 | $228 |
| Bard Peripheral Vascular, Inc. | 3 | $203 |
| Stryker | 6 | $196 |
| Livanova USA, Inc. | 2 | $176 |
| Penumbra, Inc. | 7 | $155 |
| Cardiovascular Systems Inc. | 2 | $139 |
| Edwards Lifesciences | 1 | $136 |
| Siemens Medical Solutions USA, Inc. | 1 | $112 |
| Pfizer | 6 | $112 |
| Sanofi-aventis U.S. LLC | 4 | $100 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $98 |
| Merck | 5 | $93 |
| W. L. Gore & Associates, Inc. | 2 | $84 |
| Novartis | 3 | $52 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $47 |
| Imperative Care, Inc | 3 | $44 |
| Philips North America LLC | 2 | $41 |
| Baxter Healthcare | 1 | $36 |
| Astellas Pharma US Inc | 1 | $23 |
| Cardiva Medical, Inc. | 1 | $21 |
| Cvrx, Inc. | 1 | $15 |
| Johnson & Johnson | 1 | $15 |
| Boehringer Ingelheim | 1 | $15 |
| Azurity Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FLOWTRIEVER CATHETER, S$4,302
- CT THROMBECTOMY SYSTEM KIT$4,302
- RESOLUTE ONYX$4,214
- VersaCross Access Solution$1,752
- Resolute$1,416
- GENERAL - STENTS$1,400
- AlphaVac$820
- COREVALVE EVOLUT R$437
- GENERAL ATHERECTOMY$349
- HeartMate 3 Left Ventricular Assist Device$287
- Impella$269
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$265
- AVVIGO Guidance System$253
- Micra$229
- Ensite Cardiac Mapping System$214
- Repatha$212
- GENERAL VASCULAR ACCESS$186
- SUPERA$159
- TandemLife$148
- ELIQUIS$142
How this compares
$24,296 in reported general payments places this provider in the 85th percentile of 144 cardiovascular disease providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 156 | $136,502 |
| JardianceEmpagliflozin | 73 | $76,251 |
| EntrestoSacubitril/Valsartan | 57 | $53,477 |
| XareltoRivaroxaban | 17 | $21,787 |
| OzempicSemaglutide | 13 | $19,383 |
| Repatha SureclickEvolocumab | 23 | $15,513 |
| BrilintaTicagrelor | 11 | $11,611 |
| Metoprolol Succinate | 164 | $1,397 |
| Amiodarone Hcl | 41 | $1,184 |
| Amlodipine Besylate | 285 | $925 |
| Losartan Potassium | 144 | $859 |
| Rosuvastatin Calcium | 84 | $735 |
| ClopidogrelClopidogrel Bisulfate | 88 | $688 |
| Atorvastatin Calcium | 94 | $644 |
| Carvedilol | 117 | $607 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $112 | $136,502156 claims |
| Boehringer IngelheimJardiance | $15 | $76,25173 claims |
| NovartisEntresto | $52 | $53,47757 claims |
| Johnson & JohnsonXarelto | $15 | $21,78717 claims |
| AstraZenecaBrilinta | $228 | $11,61111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 144 cardiovascular disease providers in Mississippi.
Other cardiovascular disease in Ocean Springs
- Dharmesh PatelSouthaven$1.5M
- Barry BertoletTupelo$469K
- Donny StokesJackson$207K
- Mahmoud ZayedPascagoula$103K
- James BenslerJackson$64K
- Michael HallJackson$54K
- Hugo QuintanaPascagoula$48K
- Ediz TasanPascagoula$42K
- Lawrence LeaderHattiesburg$40K
- Matthew HannKeesler Afb$40K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.